Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A
J. Clin. Invest. Miho Nozaki, et al. 116:422 doi:10.1172/JCI26316 [Go to this article.]

Figure 2
VEGF-A reduced CNV via VEGFR-1. (A) Anti–VEGFR-1 Ab (40 pmol), but not anti–VEGFR-2 Ab (1.7 pmol), abrogated inhibition of CNV by CoCl₂, VEGF-A, and PlGF-1. *P < 0.01 compared with drug alone. Antibody against VEGFR-2 but not VEGFR-1 modestly reduced CNV compared with goat IgG (40 pmol). ^#P < 0.05 compared with goat IgG. n = 10–12 per data point. (B) VEGF-A and CoCl₂ reduced CNV in wild-type mice but increased it in Vegfr1 tk^–/– mice compared with PBS-injected fellow eyes. ^#P < 0.05 compared with PBS. n = 10 per data point. CoCl₂, 0.77 nmol; VEGF-A, 0.1 pmol; VEGF-E, 0.11 pmol.